Abstracts tagged "pregnancy"

Abstract Number: 0122 • ACR Convergence 2025
The role of low profile antiphospholipid antibodies and adverse pregnancy outcomes.
Eugenia Chock¹, Tong Wang², Areeka Memon³, Zeyan Liew⁴ and Pengfei Guo⁴, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, ³Yale New Haven Health, New Haven, CT, ⁴Yale Center for Perinatal, Pediatric and Environmental Epidemiology, New Haven
Background/Purpose: Presence of high titer antiphospholipid antibodies (aPLs) confer adverse pregnancy outcomes (APOs). Patients with low titer aPLs often receive conflicting counseling on treatment, many…
Abstract Number: 2628 • ACR Convergence 2025
Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia
Daniele Marcy¹, Nanette Santoro², Claudia Lugo³, Kristin Sturm² and Kristen Demoruelle⁴, ¹University of Colorado, Northglenn, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado, Denver, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: Several systemic autoimmune diseases are associated with an increased risk of preeclampsia. Preeclampsia is a pregnancy complication characterized by new-onset hypertension after 20 weeks…
Abstract Number: 2212 • ACR Convergence 2025
Impact of the 2020 ACR Reproductive Health Guidelines on Treatment Strategies and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
Hiromi Shimada¹, Rina Mino², Taichi Miyagi³, Koichi Sugihara², Yusuke Ushio³, Mao Mizusaki², Kanako Chujo³, Naoto Manabe³, Mayuko Wada², Shusaku Nakashima² and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Women with systemic lupus erythematosus (SLE) are at increased risks for adverse pregnancy outcomes (APOs) including preterm birth, low birth weight and preeclampsia (1,2).…
Abstract Number: 1834 • ACR Convergence 2025
Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy
Rodolfo Martinez-Canales¹, Eva Abigaid Galindo-Calvillo², Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³, Cassandra Michele Skinner-Taylor², Mario Cesar Salinas-Carmona¹ and Noe Macias-Segura¹, ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Preeclampsia (PE) is a serious complication of pregnancy associated with significant maternal and fetal outcomes. Systemic lupus erythematosus (SLE) significantly increases the risk of…
Abstract Number: 2627 • ACR Convergence 2025
Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study
Shenthuraan Tharmarajah¹, Dharini Mahendira², Swaleh Hussain¹, Howard Berger³, Sara Guilcher⁴, Lisa McCarthy⁴ and Mina Tadrous¹, ¹University of Toronto, Toronto, ON, Canada, ²St Michael's Hospital, Toronto, Canada, ³St. Michael's Hospital, Toronto, Canada, ⁴University of Toronto, Toronto, Canada
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are the primary class of drug therapies generally used to treat rheumatic diseases, such as rheumatoid arthritis (RA), systemic lupus…
Abstract Number: 2213 • ACR Convergence 2025
Awareness Regarding Contraceptive Measures, Drug Usage And Factors Affecting Pregnancy Among Patients With Autoimmune Rheumatic Diseases
Juhi Dixit, Shri Balaji Institute of Medical Sciences, Mowa Raipur, Raipur, Chhattisgarh, India
Background/Purpose: This study aims to find out knowledge, attitude, practices and beliefs of patients with autoimmune rheumatic diseases regarding family planning, contraception, drug use and…
Abstract Number: 1398 • ACR Convergence 2025
Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
R. Mohamad Javier¹, Bernadus Bramantyo², Arkan Berlian³, Mahardika Nugraha⁴, Azzura Simanulang¹, Eko Setyo Herwanto⁵, Athaya Febriantyo Purnomo⁶, Jonathan Jonathan⁷, Ananingati Ananingati⁵, Budi Prakoso⁸ and Aisyah Rizki Nirmala Hanum⁵, ¹University of Indonesia Hospital, Jakarta Selatan, Jakarta Raya, Indonesia, ²Sardjito General Hospital, Daerah Istimewa Yogyakarta, Yogyakarta, Indonesia, ³Dr. Cipto Mangunkusumo Hospital, Jakarta Barat, Jakarta Raya, Indonesia, ⁴Universitas Islam Sultan Agung, KOTA SEMARANG, Jawa Tengah, Indonesia, ⁵Universitas Muhammadiyah Malang, Malang, Jawa Timur, Indonesia, ⁶Saiful Anwar General Hospita, Malang, Jawa Timur, Indonesia, ⁷RSUD Kalideres, Jakarta, Jakarta Raya, Indonesia, ⁸Department of Internal Medicine, RST dr Soepraoen, Malang, Jawa Timur, Indonesia
Background/Purpose: Autoimmune rheumatic diseases such as Sjögren’s Syndrome (SS) and Systemic Sclerosis (SSc) can significantly impact reproductive health and increase maternal cardiovascular risk. These conditions…
Abstract Number: 2563 • ACR Convergence 2025
Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review
Olivia Novosel¹, Sabrina Chiodo¹, Yanara Marks¹, Lux Li¹, Renee Gabrielle Fajardo¹, Lauren Tailor¹, Lucy Zhao¹, Jessie Cunningham², Cristina Longo³ and Sonia Grandi¹, ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, Toronto, ON, Canada, ²Health Sciences Library, The Hospital for Sick Children, Toronto, ON, Canada, Toronto, ON, Canada, ³Faculty of Pharmacy, University of Montreal, Montréal, QC, Canada, Montreal, ON, Canada
Background/Purpose: Autoimmune disorders (AD) disproportionately affect women of reproductive age, presenting challenges for disease management during the preconception and perinatal periods. Treatment decisions are complicated…
Abstract Number: 2211 • ACR Convergence 2025
Maternal Adverse Pregnancy Outcomes and Risk Factors in Patients with Systemic Lupus Erythematosus in the United States
Grace Haeun Lee¹, Jacquelyn Nestor², Baijun Zhou³ and April Jorge², ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Boston
Background/Purpose: Despite significant advances in SLE management, women with systemic lupus erythematosus (SLE) are at risk of adverse pregnancy outcomes (APOs). We sought to determine…
Abstract Number: 1391 • ACR Convergence 2025
Assessment of Anti-SSA/Ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Mala Masson¹, Bettina Cuneo², Philip Carlucci³, Peter Izmirly⁴, Justin Brandt⁵, Colin Phoon⁶, Ashley Roman⁶, Amit Saxena⁷, Michael Belmont⁵, Christina Penfield⁶, Young Mi Lee⁶, Julie Nusbaum⁵, Andrew Rubenstein⁶, Elena Sinkovskaya⁸, Alfred Abuhamad⁸, Gary Satou⁹, Whitnee Hogan¹⁰, Anita Moon-Grady¹¹, Lisa Howley¹², Mary Donofrio¹³, Stephanie Levasseur¹⁴, Miwa Geiger¹⁵, Sonal Owens¹⁶, Kristopher Cumbermack¹⁷, Jyothi Matta¹⁸, Gary Joffe¹⁹, Christopher Lindblade²⁰, Caitlin Haxel²¹, Katherine Kohari²², Joshua Copel²², James Strainic²³, Tam Doan²⁴, Conisha Holloman²⁴, Stacy Killen²⁵, Theresa Tacy²⁶, Michelle Kaplinski²⁶, Nalani Sachan⁶, Nicola Fraser⁶, Robert Clancy¹⁴ and Jill Buyon⁶, ¹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ²University of Arizona College of Medicine, Tucson, AZ, ³New York University School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁸Eastern Virginia Medical School, Norfolk, VA, ⁹University of California Los Angeles, Los Angeles, CA, ¹⁰University of Utah, Salt Lake City, UT, ¹¹University of California San Francisco, San Francisco, CA, ¹²Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹³Children's National Hospital, Washington, DC, ¹⁴Columbia University, New York, NY, ¹⁵Mount Sinai School of Medicine, New York, NY, ¹⁶University of Michigan, Ann Arbo, MI, ¹⁷University of Kentucky, Lexington, KY, ¹⁸University of Louisville, Louisville, KY, ¹⁹Perinatal Associates of New Mexico, Albuquerque, NM, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Vermont Children's Hospital, Burlington, VT, ²²Yale University, New Haven, CT, ²³UH Rainbow Babies, Cleveland, OH, ²⁴Baylor College of Medicine, Houston, TX, ²⁵Vanderbilt University, Nashville, TN, ²⁶Stanford University, Stanford, CA
Background/Purpose: For women with Sjögren's disease, the risk of Fetal Atrioventricular Block (fAVB) is a critical aspect in pregnancy counseling. To date, the most reliable…
Abstract Number: 2457 • ACR Convergence 2025
Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
Kenza El Ouazzani¹, Nathalie Morel¹, Delphine Beghin², Gaelle GUETTROT-IMBERT³, Noémie JOURDE-CHICHE⁴, Alban DEROUX⁵, Françoise Sarrot-Reynauld⁵, Lionel Couzi¹, Vincent Langlois⁶, Estibaliz LAZARO⁷, Pauline ORQUEVAUX⁸, Benjamin DE SAINTE MARIE⁹, Kevin Deve¹⁰, christophe Deligny¹¹, Nicole Ferreira¹², Bertrand Godeau¹³, Véronique Le Guern³, Raphaelle Meunier¹⁴, Elisabeth Pasquier¹⁵, Viviane Queyrel Moranne¹⁶, Laurent Sailler¹⁷, Cécile Saint-Pastou¹⁸, Nathalie Costedoat-Chalumeau³, Benoit Marin¹⁹ and Christophe Richez¹, ¹Bordeaux University Hospital, Bordeaux, France, ²Paris Pitié-Salpêtrière Hospital, Paris, France, ³Cochin Hospital, Paris, France, ⁴Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France., Marseille, France, ⁵Grenoble university hospital, Grenoble, France, ⁶Le Havre University Hospital, Le Havre, France, ⁷Bordeaux University Hospital, Pessac, France, ⁸Reims University Hospital, Reims, France, ⁹Timone university hospital, Marseille, France, ¹⁰Bayonne hospital, Bayonne, France, ¹¹Fort-de-France hospital, Fort-de-France, France, ¹²Tours University Hospital, Tours, France, ¹³Creteil Hospital, Paris, France, ¹⁴Libourne Hospital, Libourne, France, ¹⁵Brest University Hospital, Brest, France, ¹⁶Nice University Hospital, Nice, France, ¹⁷CHU Toulouse, Toulouse, France, ¹⁸Saint-Pierre Hospital, Saint-Pierre, France, ¹⁹Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) may be associated with high-risk pregnancies, especially in the presence of specific predisposing factors. While optimal disease control during pregnancy…
Abstract Number: 2209 • ACR Convergence 2025
Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
cristiana Sieiro¹, Jose Ordas Martínez², Ana Merino³, Helena Amar Muñoz⁴, Stefanie Burger⁵, Ignacio Braña Abascal⁵, Carmen Jose Mendéz⁶, Raquel Dos Santos Sobrín⁷, Jose Luis Puga Guzman⁷, Ricardo Blanco⁸ and Víctor Taboada Martínez³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Marqués de Valdecilla, Santader, Spain,, Santander, Spain, ⁴Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain, Oviedo, Spain, ⁶Complexo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain, Coruña, Spain, ⁷Hospital Universitario de Santiago de Compostela, Rheumatology, Santiago de Compostela,, Santiago de Compostela, Spain, ⁸Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is associated with significant maternal and obstetric risks, particularly in the context of antiphospholipid syndrome (APS).…
Abstract Number: 1177 • ACR Convergence 2025
Pregnancy Outcomes in Women with Familial Mediterranean Fever Treated with Anakinra: A Retrospective Study
Bilgesu Ergezen¹, Ozgur Can Kilinc², Bugra Egeli³, Oguzhan Omer Kizilkaya², Kerem parlar⁴, Enes Azman², Huri ozdogan¹ and serdal Ugurlu⁵, ¹Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, İstanbul, Turkey, ²Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ³Children's Hospital of Los Angeles, Los Angeles, CA, ⁴Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease mainly treated with colchicine. Anakinra, an interleukin-1 receptor antagonist, is used for colchicine-resistant cases. However, data…
Abstract Number: 2413 • ACR Convergence 2025
Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Mariana Gonzalez-Treviño¹, Ashley L Ciosek¹, Genessis Maldonado¹, Catherine Deffendall², Tania Ruiz¹, Tracy Frech¹ and Rashmi Dhital³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Vanderbilt University Medical Center, Brentwood, TN
Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in SLE during pregnancy. An adverse effect of HCQ includes cardiotoxicity. Hormonal changes during pregnancy may trigger SLE…
Abstract Number: 2210 • ACR Convergence 2025
Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis
Dahima Cintron¹, Amanda Eudy², Michelle Petri³, Rebecca Fischer-Betz⁴, Abeer Mockbel⁵, Cecilia Nalli⁶, Laura Andreoli⁷, Angela Tincani⁸, Yair Molad⁹, Dafna D. Gladman¹⁰, Murray Urowitz¹¹, Stephen Balevic¹² and Megan Clowse¹³, ¹Duke Health, Durham, NC, ²Duke University, Raleigh, NC, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁵Cairo University/Kasr- AlAiny Medical School, Cairo, Egypt, ⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁷University of Brescia, Brescia, Brescia, Italy, ⁸ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ⁹Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Duke University, Durham, NC, ¹³Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE experience higher rates of adverse pregnancy outcomes. Among those with active SLE during pregnancy, lupus nephritis (LN) is associated with particularly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].